CN1349423A - 包含曲马多物质和选择性cox－2抑制剂药物的组合物 - Google Patents

包含曲马多物质和选择性cox－2抑制剂药物的组合物 Download PDF

Info

Publication number
CN1349423A
CN1349423A CN00807066A CN00807066A CN1349423A CN 1349423 A CN1349423 A CN 1349423A CN 00807066 A CN00807066 A CN 00807066A CN 00807066 A CN00807066 A CN 00807066A CN 1349423 A CN1349423 A CN 1349423A
Authority
CN
China
Prior art keywords
pharmaceutical composition
inhibitor
tramadol
medicine
selective cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00807066A
Other languages
English (en)
Chinese (zh)
Inventor
E·E·科德
R·P·马蒂内兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1349423A publication Critical patent/CN1349423A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN00807066A 1999-03-01 2000-02-29 包含曲马多物质和选择性cox－2抑制剂药物的组合物 Pending CN1349423A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12202699P 1999-03-01 1999-03-01
US60/122,026 1999-03-01

Publications (1)

Publication Number Publication Date
CN1349423A true CN1349423A (zh) 2002-05-15

Family

ID=22400139

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00807066A Pending CN1349423A (zh) 1999-03-01 2000-02-29 包含曲马多物质和选择性cox－2抑制剂药物的组合物

Country Status (9)

Country Link
EP (1) EP1156855A1 (ja)
JP (1) JP2002538176A (ja)
CN (1) CN1349423A (ja)
AU (1) AU3384200A (ja)
CA (1) CA2364127A1 (ja)
HK (1) HK1040945A1 (ja)
MX (1) MXPA01008903A (ja)
NZ (1) NZ513924A (ja)
WO (1) WO2000051685A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573824A (zh) * 2009-10-16 2012-07-11 埃斯蒂文博士实验室股份有限公司 治疗疼痛的包含曲马多和塞来昔布的组合物
CN102946871A (zh) * 2010-06-04 2013-02-27 埃斯蒂文博士实验室股份有限公司 曲马多和昔布类（Coxibs）的共晶体的药物组合物

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795332B2 (en) 2002-09-30 2014-08-05 Ethicon, Inc. Barbed sutures
ATE284691T1 (de) * 1998-11-02 2005-01-15 Merck & Co Inc Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
US6773450B2 (en) 2002-08-09 2004-08-10 Quill Medical, Inc. Suture anchor and method
US8100940B2 (en) 2002-09-30 2012-01-24 Quill Medical, Inc. Barb configurations for barbed sutures
ES2819854T3 (es) 2002-11-22 2021-04-19 Gruenenthal Gmbh Uso de (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol para tratar el dolor inflamatorio
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
US20070293542A1 (en) * 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
ES2638301T3 (es) 2004-05-14 2017-10-19 Ethicon Llc Dispositivos de sutura
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
SE532177C2 (sv) * 2006-07-24 2009-11-10 P & P Ab En punkteringsanordning för en uppblåsbar enhet
EP2610244A1 (en) 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
US20080255612A1 (en) 2007-04-13 2008-10-16 Angiotech Pharmaceuticals, Inc. Self-retaining systems for surgical procedures
ES2488406T3 (es) 2007-09-27 2014-08-27 Ethicon Llc Suturas de auto-retención que incluyen elementos de retención a tejido con resistencia mejorada
US8916077B1 (en) 2007-12-19 2014-12-23 Ethicon, Inc. Self-retaining sutures with retainers formed from molten material
US8118834B1 (en) 2007-12-20 2012-02-21 Angiotech Pharmaceuticals, Inc. Composite self-retaining sutures and method
EP3533399A3 (en) 2008-02-21 2019-10-23 Ethicon LLC Method for elevating retainers on self-retaining sutures
CA2720847C (en) 2008-04-15 2016-06-28 Angiotech Pharmaceuticals, Inc. Self-retaining sutures with bi-directional retainers or uni-directional retainers
AR073495A1 (es) * 2008-09-05 2010-11-10 Gruenenthal Gmbh Combinacion farmaceutica que contiene el 6-dimetilaminometil-1- (3-metoxi-fenil)-ciclohexano-1,3-diol y un nsaid
EP2331087A1 (en) * 2008-09-05 2011-06-15 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
SG196767A1 (en) 2008-11-03 2014-02-13 Ethicon Llc Length of self-retaining suture and method and device for using the same
EP2586432A3 (en) * 2009-10-16 2013-07-10 Laboratorios Del Dr. Esteve, S.A. Co-crystals of Tramadol and NSAIDs like Coxibs
WO2011090628A2 (en) 2009-12-29 2011-07-28 Angiotech Pharmaceuticals, Inc. Bidirectional self-retaining sutures with laser-marked and/or non-laser marked indicia and methods
EP2353594A1 (en) * 2010-02-09 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising tramadol and the co-crystal of celecoxib and L-proline in the treatment of pain
NZ603886A (en) 2010-05-04 2014-12-24 Ethicon Llc Self-retaining systems having laser-cut retainers
BR112012031606B1 (pt) 2010-06-11 2020-11-10 Ethicon Llc distribuidor de sutura
RU2608237C2 (ru) 2010-11-03 2017-01-17 ЭТИКОН ЭлЭлСи Самоудерживающиеся шовные материалы, выделяющие лекарственные средства, и относящиеся к ним методы
NZ704802A (en) 2010-11-09 2015-12-24 Ethicon Llc Emergency self-retaining sutures and packaging
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
AU2012230716B2 (en) 2011-03-23 2016-05-19 Ethicon Llc Self-retaining variable loop sutures
US20130172931A1 (en) 2011-06-06 2013-07-04 Jeffrey M. Gross Methods and devices for soft palate tissue elevation procedures
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
EP3682876A4 (en) * 2017-09-15 2021-06-16 Crystalgenomics, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN WITH POLMACOXIB AND TRAMADOL
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
DK0920422T3 (da) * 1996-08-14 2003-03-17 Searle & Co Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
WO1998050075A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
WO2000029022A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573824A (zh) * 2009-10-16 2012-07-11 埃斯蒂文博士实验室股份有限公司 治疗疼痛的包含曲马多和塞来昔布的组合物
CN107050006A (zh) * 2009-10-16 2017-08-18 埃斯蒂文博士实验室股份有限公司 治疗疼痛的包含曲马多和塞来昔布的组合物
CN102946871A (zh) * 2010-06-04 2013-02-27 埃斯蒂文博士实验室股份有限公司 曲马多和昔布类（Coxibs）的共晶体的药物组合物

Also Published As

Publication number Publication date
NZ513924A (en) 2001-09-28
HK1040945A1 (zh) 2002-06-28
EP1156855A1 (en) 2001-11-28
AU3384200A (en) 2000-09-21
JP2002538176A (ja) 2002-11-12
MXPA01008903A (es) 2003-07-21
CA2364127A1 (en) 2000-09-08
WO2000051685A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
CN1349423A (zh) 包含曲马多物质和选择性cox－2抑制剂药物的组合物
JP4977297B2 (ja) トラマドール物質及び抗痙攣薬を含んで成る組成物
CN1072930C (zh) 含有一种曲马多成分和一种非甾体抗炎药物的组合物
US20090253728A1 (en) Methods and Compositions for Treating Nociceptive Pain
KR20110057144A (ko) 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
JPH0144684B2 (ja)
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
KR20130111945A (ko) 통증 치료용 약제학적 병용물
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
Wang et al. Antinociceptive properties of fenfluramine, a serotonin reuptake inhibitor, in a rat model of neuropathy
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
JPS63500598A (ja) 抗けいれん剤組成物と方法
CN1543344A (zh) 治疗尿失禁的芳基(或杂芳基)氮杂茂甲醇衍生物
EP0346445A1 (en) Dextrorphan potentiator for anticonvulsant composition and method
TW457087B (en) Pharmaceutical composition for inhibiting dependency and tolerance developed by narcotic analgesic agent
US20100152152A1 (en) Therapeutic Use of Nefopam
JPH02502545A (ja) 抗ひきつけ剤組成物および方法のためのデキストロメトルファン相乗的協力剤
EA003557B1 (ru) Схема обезболивания
Ogata et al. N‐Methyl‐D‐Aspartate (NMDA) Receptor Antagonists
CN1758912A (zh) 药物·物质依赖治疗药
TW202010496A (zh) 双那布扶林己二酸酯和乙醯胺酚的藥物製劑及治療疼痛的方法
WO2003026634A1 (es) Aminas como agentes anti-alcoholismo
KR20070091911A (ko) 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
US20020137767A1 (en) Methods for treating addictive disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication